University of North Texas

About: University of North Texas is a education organization based out in Denton, Texas, United States. It is known for research contribution in the topics: Population & Poison control. The organization has 11866 authors who have published 26984 publications receiving 705376 citations. The organization is also known as: Fight, North Texas & UNT.

Cause related marketing: how generation y responds

Abstract: Generation Y, children born to baby‐boomers, is widely considered to be the next big generation. Businesses are therefore struggling to find ways to capture a piece of this market. Could cause‐related marketing be the answer? Employs an experimental design to examine how college‐age Generation Y consumers respond to a cause‐related marketing (CRM) offer based on four structural elements. Also examines the potential impacts of socio‐demographic characteristics of participants. The results indicate that a CRM offer is more likely to elicit a more positive response to a disaster cause than an ongoing cause when businesses use non‐transaction‐based and long‐term/frequent support. Finds that females, social science majors, parents’ annual income and previous donation activity have significant impact on the evaluation of a CRM offer. There is a positive relationship between evaluation of a CRM offer and purchase intent toward the offer.

Long-distance communication and signal amplification in systemic acquired resistance

Abstract: Systemic acquired resistance (SAR) is an inducible defense mechanism in plants that confers enhanced resistance against a variety of pathogens. SAR is activated in the uninfected systemic (distal) organs in response to a prior (primary) infection elsewhere in the plant. SAR is associated with the activation of salicylic acid (SA) signaling and the priming of defense responses for robust activation in response to subsequent infections. The activation of SAR requires communication by the primary infected tissues with the distal organs. The vasculature functions as a conduit for the translocation of factors that facilitate long-distance intra-plant communication. In recent years, several metabolites putatively involved in long-distance signaling have been identified. These include the methyl ester of SA (MeSA), the abietane diterpenoid dehydroabietinal (DA), the dicarboxylic acid azelaic acid (AzA), and a glycerol-3-phosphate (G3P)-dependent factor. Long-distance signaling by some of these metabolites also requires the lipid-transfer protein DIR1 (DEFECTIVE IN INDUCED RESISTANCE 1). The relative contribution of these factors in long-distance signaling is likely influenced by environmental conditions, for example light. In the systemic leaves, the AGD2-LIKE DEFENSE RESPONSE PROTEIN1 (ALD1)-dependent production of the lysine catabolite pipecolic acid (Pip), FLAVIN-DEPENDENT MONOOXYGENASE1 (FMO1) signaling, as well as SA synthesis and downstream signaling are required for the activation of SAR. This review summarizes the involvement and interaction between long-distance SAR signals and details the recently discovered role of Pip in defense amplification and priming that allows plants to acquire immunity at the systemic level. Recent advances in SA signaling and perception are also highlighted.

Copper–Nitrene Complexes in Catalytic C ? H Amination

Abstract: The direct catalytic transformation of typically inert carbon– hydrogen bonds into carbon–oxygen, carbon–nitrogen, and carbon–carbon bonds represents a significant challenge in organic synthesis and the chemical industry. Ideally, such reactions would not require the presence of a functional group that is discarded later in the course of the chemical transformation, but would proceed with atom and energy efficiency and be of minimal environmental impact. Chemical species capable of directly promoting this transformation often contain multiple bonds between late transition metals to oxygen, nitrogen, or carbon centers. Nature provides inspiration with enzymes such as cyctochrome P-450, which is efficient at inserting an oxygen atom into hydrocarbon C H bonds through an iron–oxo intermediate ([Fe]=O). The use of iminoiodanes (PhI=NR) has led to the generation of related metal–nitrene intermediates ([M]=NR), which in certain cases, exhibit stoichiometric reactivity with carbon–hydrogen bonds to give amines. Several catalytic protocols based on Rh, Ru, Ag, Au, Cu, and other metals for the amination of benzylic or allylic C H bonds with iminoiodanes bearing electrondeficient N substituents represent useful methodologies for the transformation of C H into C N bonds. 10,11] In these catalytic cases, metal–nitrene species are inferred, but their high reactivity makes their characterization as the active intermediates difficult. This lack of characterization is unfortunate, as a fundamental understanding of metal–nitrene species that mediate catalytic C N bond formation would aid the development of more general systems for C H bond functionalization. In this context, we recently isolated a dicopper complex [{(Me3NN)Cu}2(m-NAr)] (Ar = 3,5-dimethylphenyl) in which a nitrene is bound between two b-diketiminate copper fragments. Solution studies supported the intermediacy of terminal copper–nitrene [Cu] = [(Me3NN)Cu] through the dissociation of a b-diketiminate copper fragment from [{(Me3NN)Cu}2(m-NAr)]. The terminal nitrene could not be directly observed owing to an unfavorable dissociation constant [Eq. (1); [Cu] = [(Me3NN)Cu].

Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma

Abstract: Background Many children with asthma continue to experience symptoms despite available therapies. Objective This study evaluated the efficacy and safety of omalizumab, a humanized anti-IgE mAb, in children with moderate-to-severe persistent allergic (IgE-mediated) asthma that was inadequately controlled despite treatment with medium-dose or high-dose inhaled corticosteroids (ICSs) with or without other controller medications. Methods A randomized, double-blind, placebo-controlled trial enrolled children age 6 to Results A total of 627 patients (omalizumab, n=421; placebo, n=206) were randomized, with efficacy analyzed in 576 (omalizumab, n=384; placebo, n=192). Over the 24-week fixed-steroid phase, omalizumab reduced the rate of clinically significant asthma exacerbations (worsening symptoms requiring doubling of baseline ICS dose and/or systemic steroids) by 31% versus placebo (0.45 vs 0.64; rate ratio, 0.69; P = .007). Over a period of 52 weeks, the exacerbation rate was reduced by 43% versus placebo ( P Conclusion Add-on omalizumab is effective and well tolerated as maintenance therapy in children (6 to